Cfb (complement factor B) - Rat Genome Database

Send us a Message

Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   
Gene: Cfb (complement factor B) Rattus norvegicus
Symbol: Cfb
Name: complement factor B
RGD ID: 2204
Description: Predicted to enable serine-type endopeptidase activity. Involved in complement activation; response to lipopolysaccharide; and response to thyroid hormone. Located in extracellular space. Biomarker of polycystic kidney disease and retinal degeneration. Human ortholog(s) of this gene implicated in several diseases, including atypical hemolytic-uremic syndrome; autoimmune disease (multiple); eye disease (multiple); glomerulonephritis (multiple); and sickle cell anemia. Orthologous to human CFB (complement factor B); PARTICIPATES IN coagulation cascade pathway; complement system pathway; Staphylococcus aureus infection pathway; INTERACTS WITH 1,1,1-Trichloro-2-(o-chlorophenyl)-2-(p-chlorophenyl)ethane; 17alpha-ethynylestradiol; 17beta-estradiol.
Type: protein-coding
RefSeq Status: VALIDATED
Previously known as: B-factor, properdin; Bf; Da1-24; MGC94594; properdin factor B
RGD Orthologs
Green Monkey
Naked Mole-Rat
Alliance Orthologs
More Info more info ...
Allele / Splice: Cfbem1Tja  
Genetic Models: SHR-Cfbem1Tja
Latest Assembly: mRatBN7.2 - mRatBN7.2 Assembly
Rat AssemblyChrPosition (strand)SourceGenome Browsers
GRCr8203,975,271 - 3,981,138 (+)NCBIGRCr8
mRatBN7.2203,970,643 - 3,976,510 (+)NCBImRatBN7.2mRatBN7.2
mRatBN7.2 Ensembl203,951,474 - 3,976,505 (+)EnsemblmRatBN7.2 Ensembl
UTH_Rnor_SHR_Utx204,670,648 - 4,676,510 (+)NCBIRnor_SHRUTH_Rnor_SHR_Utx
UTH_Rnor_SHRSP_BbbUtx_1.0204,032,396 - 4,038,258 (+)NCBIRnor_SHRSPUTH_Rnor_SHRSP_BbbUtx_1.0
UTH_Rnor_WKY_Bbb_1.0204,569,562 - 4,575,424 (+)NCBIRnor_WKYUTH_Rnor_WKY_Bbb_1.0
Rnor_6.0204,536,206 - 4,542,073 (-)NCBIRnor6.0Rnor_6.0rn6Rnor6.0
Rnor_6.0 Ensembl204,536,212 - 4,542,073 (-)EnsemblRnor6.0rn6Rnor6.0
Rnor_6.0 Ensembl204,536,203 - 4,561,066 (-)EnsemblRnor6.0rn6Rnor6.0
Rnor_5.0206,616,005 - 6,621,872 (-)NCBIRnor5.0Rnor_5.0rn5Rnor5.0
Celera204,054,184 - 4,060,051 (-)NCBICelera
Cytogenetic Map20p12NCBI
JBrowse: View Region in Genome Browser (JBrowse)

Disease Annotations     Click to see Annotation Detail View
acute lymphoblastic leukemia  (ISO)
age related macular degeneration 14  (ISO)
age related macular degeneration 7  (ISO)
anterior uveitis  (ISO)
anti-basement membrane glomerulonephritis  (ISO)
atypical hemolytic-uremic syndrome  (ISO)
autosomal dominant polycystic kidney disease  (ISO)
Behcet's disease  (ISO)
beta thalassemia  (ISO)
boutonneuse fever  (ISO)
Brain Injuries  (ISO)
breast cancer  (ISO)
bullous pemphigoid  (ISO)
Chemically-Induced Disorders  (ISO)
Choroidal Neovascularization  (ISO)
complement component 2 deficiency  (ISO)
Complement Factor B Deficiency  (ISO)
conjunctivitis  (ISO)
diabetic retinopathy  (ISO)
end stage renal disease  (ISO)
erythema nodosum  (ISO)
Experimental Autoimmune Myasthenia Gravis  (IMP)
Experimental Autoimmune Uveoretinitis  (IMP,ISO)
factor VIII deficiency  (ISO)
focal segmental glomerulosclerosis  (ISO)
focal segmental glomerulosclerosis 1  (ISO)
genetic disease  (ISO)
IgA glomerulonephritis  (ISO)
kidney disease  (ISO)
Kidney Reperfusion Injury  (ISO)
lepromatous leprosy  (ISO)
lupus nephritis  (ISO)
macular degeneration  (ISO)
membranoproliferative glomerulonephritis  (ISO)
membranous glomerulonephritis  (ISO)
Meningococcal Infections  (ISO)
Multifocal Choroiditis  (ISO)
myasthenia gravis  (ISO)
neutropenia  (ISO)
otitis media  (ISO)
paracoccidioidomycosis  (ISO)
polycystic kidney disease  (IEP)
Polypoidal Choroidal Vasculopathy  (ISO)
proteasome-associated autoinflammatory syndrome 1  (ISO)
psoriasis  (ISO)
pyelonephritis  (ISO)
Refractory Anemia with Excess of Blasts  (ISO)
retinal degeneration  (IEP)
Sepsis  (ISO)
sickle cell anemia  (ISO)
sinusitis  (ISO)
systemic lupus erythematosus  (ISO)
systemic scleroderma  (ISO)
type 1 diabetes mellitus  (ISO)
ulcerative colitis  (ISO)

Gene-Chemical Interaction Annotations     Click to see Annotation Detail View
(-)-epigallocatechin 3-gallate  (ISO)
(1->4)-beta-D-glucan  (ISO)
1,1,1-Trichloro-2-(o-chlorophenyl)-2-(p-chlorophenyl)ethane  (EXP,ISO)
1,2-dimethylhydrazine  (ISO)
17alpha-ethynylestradiol  (EXP,ISO)
17beta-estradiol  (EXP,ISO)
17beta-estradiol 3-benzoate  (EXP)
2,3,7,8-tetrachlorodibenzodioxine  (EXP,ISO)
2,3,7,8-Tetrachlorodibenzofuran  (ISO)
2,3-dimethoxynaphthalene-1,4-dione  (ISO)
2,4,6-tribromophenol  (ISO)
2,4-dinitrotoluene  (EXP)
2-hydroxypropanoic acid  (ISO)
3,3',4,4',5-pentachlorobiphenyl  (EXP)
3,4-methylenedioxymethamphetamine  (ISO)
3-isobutyl-1-methyl-7H-xanthine  (ISO)
4,4'-diaminodiphenylmethane  (ISO)
4,4'-sulfonyldiphenol  (ISO)
4-hydroxynon-2-enal  (ISO)
4-hydroxyphenyl retinamide  (ISO)
6-propyl-2-thiouracil  (EXP)
acetamide  (EXP)
acrylamide  (EXP,ISO)
aflatoxin B1  (ISO)
all-trans-retinoic acid  (ISO)
antimony(0)  (ISO)
antirheumatic drug  (ISO)
aripiprazole  (ISO)
arsane  (ISO)
arsenic atom  (ISO)
arsenous acid  (ISO)
azoxystrobin  (EXP)
benzene  (ISO)
benzo[a]pyrene  (ISO)
benzo[b]fluoranthene  (ISO)
bis(2-chloroethyl) sulfide  (ISO)
bisphenol A  (EXP,ISO)
cadmium atom  (ISO)
cadmium dichloride  (EXP,ISO)
calcium atom  (ISO)
calcium(0)  (ISO)
carbon nanotube  (ISO)
chlordecone  (ISO)
chlorpyrifos  (EXP)
chromium atom  (ISO)
chrysene  (ISO)
cobalt dichloride  (EXP,ISO)
copper atom  (ISO)
copper(0)  (ISO)
copper(II) sulfate  (ISO)
corn oil  (EXP)
cyclophosphamide  (ISO)
cyclosporin A  (ISO)
danazol  (ISO)
dexamethasone  (ISO)
dextran sulfate  (ISO)
diallyl trisulfide  (EXP)
diarsenic trioxide  (ISO)
dichloroacetic acid  (ISO)
diethylstilbestrol  (EXP,ISO)
dipotassium bis[mu-tartrato(4-)]diantimonate(2-) trihydrate  (ISO)
diquat  (ISO)
disulfiram  (ISO)
diuron  (EXP)
doxorubicin  (ISO)
fenvalerate  (EXP)
flutamide  (EXP)
folic acid  (ISO)
fonofos  (ISO)
formaldehyde  (ISO)
furan  (EXP)
glyphosate  (EXP)
hydrogen peroxide  (ISO)
imidacloprid  (EXP)
indometacin  (ISO)
inulin  (ISO)
ketoconazole  (EXP)
L-ascorbic acid  (ISO)
lead(0)  (ISO)
lipopolysaccharide  (ISO)
magnesium atom  (ISO)
malathion  (ISO)
mercury atom  (ISO)
mercury dichloride  (ISO)
mercury(0)  (ISO)
metam  (ISO)
mifepristone  (EXP)
N-methyl-4-phenylpyridinium  (EXP)
N-nitrosodiethylamine  (EXP)
N-Nitrosopyrrolidine  (ISO)
naphthalene  (ISO)
nefazodone  (EXP)
nickel atom  (ISO)
O-methyleugenol  (ISO)
olanzapine  (ISO)
ozone  (ISO)
paclitaxel  (EXP)
paracetamol  (EXP,ISO)
parathion  (ISO)
parthenolide  (ISO)
perfluorooctane-1-sulfonic acid  (ISO)
perfluorooctanoic acid  (EXP,ISO)
phenobarbital  (ISO)
pirinixic acid  (ISO)
potassium chromate  (ISO)
potassium dichromate  (ISO)
progesterone  (ISO)
propanal  (ISO)
protein kinase inhibitor  (ISO)
quercetin  (ISO)
rac-lactic acid  (ISO)
S-(1,2-dichlorovinyl)-L-cysteine  (ISO)
silicon dioxide  (EXP,ISO)
sodium arsenate  (ISO)
sodium arsenite  (ISO)
tamoxifen  (ISO)
temozolomide  (ISO)
terbufos  (ISO)
tert-butyl hydroperoxide  (ISO)
testosterone  (EXP)
tetrachloromethane  (EXP,ISO)
tetraphene  (ISO)
thiabendazole  (EXP)
thioacetamide  (EXP)
thiram  (ISO)
titanium dioxide  (ISO)
tolcapone  (EXP)
Triptolide  (ISO)
troglitazone  (ISO)
valproic acid  (ISO)
vinclozolin  (EXP)
zinc atom  (ISO)
zinc(0)  (ISO)
zoledronic acid  (ISO)

Gene Ontology Annotations     Click to see Annotation Detail View

Cellular Component

Molecular Function

Molecular Pathway Annotations     Click to see Annotation Detail View

References - curated
# Reference Title Reference Citation
1. Biosynthesis of complement components by cultured rat hepatocytes. Anthony R, etal., Biochem J. 1985 Nov 15;232(1):93-8.
2. Complement haemolytic activity, circulating immune complexes and the morbidity of sickle cell anaemia. Anyaegbu CC, etal., APMIS. 1999 Jul;107(7):699-702.
3. Complement proteins and C3 anaphylatoxin in the tears of patients with conjunctivitis. Ballow M, etal., J Allergy Clin Immunol. 1985 Sep;76(3):473-6.
4. Complement abnormalities during an epidemic of group B meningococcal infection in children. Beatty DW, etal., Clin Exp Immunol. 1986 Jun;64(3):465-70.
5. Alternative complement pathway and factor B activities in rats with altered blood levels of thyroid hormone. Bitencourt CS, etal., Braz J Med Biol Res. 2012 Mar;45(3):216-21. Epub 2012 Mar 1.
6. Complement activation via alternative pathway is critical in the development of laser-induced choroidal neovascularization: role of factor B and factor H. Bora NS, etal., J Immunol. 2006 Aug 1;177(3):1872-8.
7. Properdin factor B and acute lymphocytic leukemia (ALL). Budowle B, etal., Cancer. 1982 Dec 1;50(11):2369-71.
8. Susceptibility to advanced age-related macular degeneration and alleles of complement factor H, complement factor B, complement component 2, complement component 3, and age-related maculopathy susceptibility 2 genes in a Mexican population. Buentello-Volante B, etal., Mol Vis. 2012;18:2518-25. Epub 2012 Oct 11.
9. Inhibition of the alternative pathway of complement activation reduces inflammation in experimental autoimmune uveoretinitis. Chen M, etal., Eur J Immunol. 2010 Oct;40(10):2870-81. doi: 10.1002/eji.201040323.
10. Complement Factor B Is a Determinant of Both Metabolic and Cardiovascular Features of Metabolic Syndrome. Coan PM, etal., Hypertension. 2017 Jul 24. pii: HYPERTENSIONAHA.117.09242. doi: 10.1161/HYPERTENSIONAHA.117.09242.
11. Complement deposition and microglial activation in the outer retina in light-induced retinopathy: inhibition by a 5-HT1A agonist. Collier RJ, etal., Invest Ophthalmol Vis Sci. 2011 Oct 11;52(11):8108-16. doi: 10.1167/iovs.10-6418.
12. Isolation and characterization of rat complement factor B and its interaction with cell-bound human C3. Daha MR and van Es LA, Immunology. 1980 Dec;41(4):849-55.
13. Classical and alternative complement pathway activation in paracoccidioidomycosis. de Messias IT and Mohren D, J Investig Allergol Clin Immunol. 1994 Mar-Apr;4(2):91-5.
14. HLA-linked complement polymorphisms (C2, BF) in psoriasis. Dewald G, etal., Arch Dermatol Res. 1983;275(5):301-4.
15. Aberrant expression of acute-phase reactant proteins in sera and breast lesions of patients with malignant and benign breast tumors. Doustjalali SR, etal., Electrophoresis. 2004 Jul;25(14):2392-401.
16. Analysis of major alleles associated with age-related macular degeneration in patients with multifocal choroiditis: strong association with complement factor H. Ferrara DC, etal., Arch Ophthalmol. 2008 Nov;126(11):1562-6. doi: 10.1001/archopht.126.11.1562.
17. Phylogenetic-based propagation of functional annotations within the Gene Ontology consortium. Gaudet P, etal., Brief Bioinform. 2011 Sep;12(5):449-62. doi: 10.1093/bib/bbr042. Epub 2011 Aug 27.
18. Gain-of-function mutations in complement factor B are associated with atypical hemolytic uremic syndrome. Goicoechea de Jorge E, etal., Proc Natl Acad Sci U S A. 2007 Jan 2;104(1):240-5. Epub 2006 Dec 20.
19. Proteomic analysis of the LPS-induced stress response in rat chondrocytes reveals induction of innate immune response components in articular cartilage. Haglund L, etal., Matrix Biol. 2008 Mar;27(2):107-18. Epub 2007 Oct 10.
20. The complement system in Mediterranean spotted fever. Herrero-Herrero JI, etal., J Infect Dis. 1988 May;157(5):1093-5.
21. The involvement of complement factor B and complement component C2 in an Indian cohort with age-related macular degeneration. Kaur I, etal., Invest Ophthalmol Vis Sci. 2010 Jan;51(1):59-63. doi: 10.1167/iovs.09-4135. Epub 2009 Aug 20.
22. Association of polymorphisms in C2, CFB and C3 with exudative age-related macular degeneration in a Korean population. Kim SJ, etal., Exp Eye Res. 2012 Mar;96(1):42-7. doi: 10.1016/j.exer.2012.01.005. Epub 2012 Jan 18.
23. Allotyping human complement factor B in Asian Indian type 1 diabetic patients. Kumar N, etal., Tissue Antigens. 2008 Dec;72(6):517-24. Epub 2008 Sep 29.
24. Acute phase proteins, C9, factor B, and lysozyme in recurrent oral ulceration and Behcet's syndrome. Lehner T and Adinolfi M, J Clin Pathol. 1980 Mar;33(3):269-75.
25. The alternative pathway of complement is activated in the glomeruli and tubulointerstitium of mice with adriamycin nephropathy. Lenderink AM, etal., Am J Physiol Renal Physiol. 2007 Aug;293(2):F555-64. Epub 2007 May 23.
26. Mutations in alternative pathway complement proteins in American patients with atypical hemolytic uremic syndrome. Maga TK, etal., Hum Mutat. 2010 Jun;31(6):E1445-60. doi: 10.1002/humu.21256.
27. Inhibition of complement alternative pathway suppresses experimental autoimmune anterior uveitis by modulating T cell responses. Manickam B, etal., J Biol Chem. 2011 Mar 11;286(10):8472-80. doi: 10.1074/jbc.M110.197616. Epub 2011 Jan 7.
28. Rat ISS GO annotations from MGI mouse gene data--August 2006 MGD data from the GO Consortium
29. Activated complement in inflamed aqueous humor. Mondino BJ, etal., Invest Ophthalmol Vis Sci. 1984 Jul;25(7):871-3.
30. Significance of C2/CFB variants in age-related macular degeneration and polypoidal choroidal vasculopathy in a Japanese population. Nakata I, etal., Invest Ophthalmol Vis Sci. 2012 Feb 16;53(2):794-8. doi: 10.1167/iovs.11-8468.
31. Role of different pathways of the complement cascade in experimental bullous pemphigoid. Nelson KC, etal., J Clin Invest. 2006 Nov;116(11):2892-900. Epub 2006 Oct 5.
32. Factor B subtypes in Japanese patients with IgA nephropathy and with idiopathic membranous nephropathy. Nishimukai H, etal., Exp Clin Immunogenet. 1988;5(4):196-202.
33. Immunoglobulin classes, complement factors and circulating immune complexes in chronic sinusitis patients. Ogunleye AO and Arinola OG, Afr J Med Med Sci. 2001 Dec;30(4):309-12.
34. OMIM Disease Annotation Pipeline OMIM Disease Annotation Pipeline
35. Hypercomplementemia in adult patients with IgA nephropathy. Onda K, etal., J Clin Lab Anal. 2007;21(2):77-84.
36. Elevated plasma levels of the immunosuppressive complement fragment Ba in renal failure. Oppermann M, etal., Kidney Int. 1991 Nov;40(5):939-47.
37. C3, C4, factor B and HLA-DR alpha mRNA expression in renal biopsy specimens from patients with IgA nephropathy. Oren R, etal., Immunology. 1995 Dec;86(4):575-83.
38. Local extrahepatic expression of complement genes C3, factor B, C2, and C4 is increased in murine lupus nephritis. Passwell J, etal., J Clin Invest. 1988 Nov;82(5):1676-84.
39. Association of c3 gene polymorphisms with neovascular age-related macular degeneration in a chinese population. Pei XT, etal., Curr Eye Res. 2009 Aug;34(8):615-22.
40. Uncontrolled C3 activation causes membranoproliferative glomerulonephritis in mice deficient in complement factor H. Pickering MC, etal., Nat Genet 2002 Aug;31(4):424-8.
41. KEGG Annotation Import Pipeline Pipeline to import KEGG annotations from KEGG into RGD
42. Genetic polymorphism of C3 and Bf in IgA nephropathy. Rambausek M, etal., Nephrol Dial Transplant. 1987;2(4):208-11.
43. GOA pipeline RGD automated data pipeline
44. ClinVar Automated Import and Annotation Pipeline RGD automated import pipeline for ClinVar variants, variant-to-disease annotations and gene-to-disease annotations
45. Data Import for Chemical-Gene Interactions RGD automated import pipeline for gene-chemical interactions
46. Comprehensive gene review and curation RGD comprehensive gene curation
47. Analysis of rare variants in the complement component 2 (C2) and factor B (BF) genes refine association for age-related macular degeneration (AMD). Richardson AJ, etal., Invest Ophthalmol Vis Sci. 2009 Feb;50(2):540-3. doi: 10.1167/iovs.08-2423. Epub 2008 Sep 20.
48. Breakdown product of factor B as an index of complement activation in lepromatous leprosy and its relation with bacillary load. Saha K, etal., Scand J Immunol. 1983 Jan;17(1):37-43.
49. [Immunological study in sickle cell disease patients: importance of the complement system]. Sassi F, etal., Tunis Med. 2003 Mar;81(3):195-9.
50. Significance of glomerular activation of the alternative pathway and lectin pathway in lupus nephritis. Sato N, etal., Lupus. 2011 Nov;20(13):1378-86. doi: 10.1177/0961203311415561. Epub 2011 Sep 5.
51. Comprehensive evaluation of complement components in the course of type I (Lepra) and type II (ENL) reactions. Sehgal VN, etal., Int J Dermatol. 1989 Jan-Feb;28(1):32-5.
52. Activation of the complement system in systemic sclerosis. Relationship to clinical severity. Senaldi G, etal., Arthritis Rheum. 1989 Oct;32(10):1262-7.
53. Elevated IgG and decreased complement component C3 and factor B in B-thalassaemia major. Sinniah D and Yadav M, Acta Paediatr Scand. 1981 Jul;70(4):547-50.
54. Fragment Bb: evidence for activation of the alternative pathway of the complement system in pregnant women with acute pyelonephritis. Soto E, etal., J Matern Fetal Neonatal Med. 2010 Oct;23(10):1085-90. doi: 10.3109/14767051003649870.
55. C3 R102G polymorphism increases risk of age-related macular degeneration. Spencer KL, etal., Hum Mol Genet. 2008 Jun 15;17(12):1821-4. doi: 10.1093/hmg/ddn075. Epub 2008 Mar 6.
56. Autoantibody to complement neoantigens in membranoproliferative glomerulonephritis. Strife CF, etal., J Pediatr. 1990 May;116(5):S98-102.
57. Excessive activation of the alternative complement pathway in autosomal dominant polycystic kidney disease. Su Z, etal., J Intern Med. 2014 Feb 4. doi: 10.1111/joim.12214.
58. A novel antibody against human factor B that blocks formation of the C3bB proconvertase and inhibits complement activation in disease models. Subias M, etal., J Immunol. 2014 Dec 1;193(11):5567-75. doi: 10.4049/jimmunol.1402013. Epub 2014 Oct 29.
59. Complement activation in type 1 human diabetes. Sundsmo JS, etal., Clin Immunol Immunopathol. 1985 May;35(2):211-25.
60. Complement alternative pathway activation in the autologous phase of nephrotoxic serum nephritis. Thurman JM, etal., Am J Physiol Renal Physiol. 2012 Jun 15;302(12):F1529-36. doi: 10.1152/ajprenal.00422.2011. Epub 2012 Apr 4.
61. Treatment with an inhibitory monoclonal antibody to mouse factor B protects mice from induction of apoptosis and renal ischemia/reperfusion injury. Thurman JM, etal., J Am Soc Nephrol. 2006 Mar;17(3):707-15. Epub 2006 Feb 8.
62. Lack of a functional alternative complement pathway ameliorates ischemic acute renal failure in mice. Thurman JM, etal., J Immunol. 2003 Feb 1;170(3):1517-23.
63. Enhanced susceptibility to acute pneumococcal otitis media in mice deficient in complement C1qa, factor B, and factor B/C2. Tong HH, etal., Infect Immun. 2010 Mar;78(3):976-83. doi: 10.1128/IAI.01012-09. Epub 2010 Jan 11.
64. Circulating immune complexes and complement levels in hemophilic children. Verroust F, etal., J Clin Lab Immunol. 1981 Sep;6(2):127-30.
65. [Changes of the complement system in myelodysplastic syndromes]. Villaescusa Blanco R, etal., Sangre (Barc). 1998 Jun;43(3):210-2.
66. Association of CFH and CFB gene polymorphisms with retinopathy in type 2 diabetic patients. Wang J, etal., Mediators Inflamm. 2013;2013:748435. doi: 10.1155/2013/748435. Epub 2013 Jun 24.
67. Modulation of renal disease in MRL/lpr mice genetically deficient in the alternative complement pathway factor B. Watanabe H, etal., J Immunol. 2000 Jan 15;164(2):786-94.
68. Association between polymorphisms of complement pathway genes and age-related macular degeneration in a Chinese population. Wu L, etal., Invest Ophthalmol Vis Sci. 2013 Jan 7;54(1):170-4. doi: 10.1167/iovs.12-10453.
69. Genetic mapping of C4 and Bf complement genes in the rat major histocompatibility complex. Wurst W, etal., Immunogenetics 1988;28(1):57-60.
70. Bf and C4 phenotypes in patients with psoriasis. Wyatt RJ, etal., Acta Derm Venereol Suppl (Stockh). 1989;146:211-3.
71. Association of C2 and CFB polymorphisms with anterior uveitis. Yang MM, etal., Invest Ophthalmol Vis Sci. 2012 Jul 27;53(8):4969-74. doi: 10.1167/iovs.12-9478.
72. Complement factor B is the downstream effector of TLRs and plays an important role in a mouse model of severe sepsis. Zou L, etal., J Immunol. 2013 Dec 1;191(11):5625-35. doi: 10.4049/jimmunol.1301903. Epub 2013 Oct 23.
Additional References at PubMed
PMID:8889548   PMID:9238044   PMID:12477932   PMID:16502470   PMID:22516433   PMID:23376485   PMID:23533145   PMID:27564415  


Comparative Map Data
(Rattus norvegicus - Norway rat)
Rat AssemblyChrPosition (strand)SourceGenome Browsers
GRCr8203,975,271 - 3,981,138 (+)NCBIGRCr8
mRatBN7.2203,970,643 - 3,976,510 (+)NCBImRatBN7.2mRatBN7.2
mRatBN7.2 Ensembl203,951,474 - 3,976,505 (+)EnsemblmRatBN7.2 Ensembl
UTH_Rnor_SHR_Utx204,670,648 - 4,676,510 (+)NCBIRnor_SHRUTH_Rnor_SHR_Utx
UTH_Rnor_SHRSP_BbbUtx_1.0204,032,396 - 4,038,258 (+)NCBIRnor_SHRSPUTH_Rnor_SHRSP_BbbUtx_1.0
UTH_Rnor_WKY_Bbb_1.0204,569,562 - 4,575,424 (+)NCBIRnor_WKYUTH_Rnor_WKY_Bbb_1.0
Rnor_6.0204,536,206 - 4,542,073 (-)NCBIRnor6.0Rnor_6.0rn6Rnor6.0
Rnor_6.0 Ensembl204,536,212 - 4,542,073 (-)EnsemblRnor6.0rn6Rnor6.0
Rnor_6.0 Ensembl204,536,203 - 4,561,066 (-)EnsemblRnor6.0rn6Rnor6.0
Rnor_5.0206,616,005 - 6,621,872 (-)NCBIRnor5.0Rnor_5.0rn5Rnor5.0
Celera204,054,184 - 4,060,051 (-)NCBICelera
Cytogenetic Map20p12NCBI
(Homo sapiens - human)
Human AssemblyChrPosition (strand)SourceGenome Browsers
GRCh38631,946,095 - 31,952,084 (+)NCBIGRCh38GRCh38hg38GRCh38
GRCh38.p14 Ensembl631,945,650 - 31,952,086 (+)EnsemblGRCh38hg38GRCh38
GRCh37631,913,872 - 31,919,861 (+)NCBIGRCh37GRCh37hg19GRCh37
Build 36632,021,752 - 32,027,839 (+)NCBINCBI36Build 36hg18NCBI36
Build 34632,021,760 - 32,027,839NCBI
Celera633,513,483 - 33,519,623 (+)NCBICelera
Cytogenetic Map6p21.33NCBI
HuRef631,700,690 - 31,706,830 (+)NCBIHuRef
CHM1_1631,915,802 - 31,921,942 (+)NCBICHM1_1
T2T-CHM13v2.0631,799,300 - 31,805,289 (+)NCBIT2T-CHM13v2.0
(Mus musculus - house mouse)
Mouse AssemblyChrPosition (strand)SourceGenome Browsers
GRCm391735,075,350 - 35,081,492 (-)NCBIGRCm39GRCm39mm39
GRCm39 Ensembl1735,075,350 - 35,081,494 (-)EnsemblGRCm39 Ensembl
GRCm381734,856,374 - 34,862,514 (-)NCBIGRCm38GRCm38mm10GRCm38
GRCm38.p6 Ensembl1734,856,374 - 34,862,518 (-)EnsemblGRCm38mm10GRCm38
MGSCv371734,993,319 - 34,999,459 (-)NCBIGRCm37MGSCv37mm9NCBIm37
MGSCv361734,464,437 - 34,470,273 (-)NCBIMGSCv36mm8
Celera1737,951,682 - 37,957,822 (-)NCBICelera
Cytogenetic Map17B1NCBI
cM Map1718.41NCBI
(Chinchilla lanigera - long-tailed chinchilla)
Chinchilla AssemblyChrPosition (strand)SourceGenome Browsers
ChiLan1.0 EnsemblNW_004955437461,235 - 470,464 (+)EnsemblChiLan1.0
ChiLan1.0NW_004955437461,235 - 466,908 (+)NCBIChiLan1.0ChiLan1.0
(Pan paniscus - bonobo/pygmy chimpanzee)
Bonobo AssemblyChrPosition (strand)SourceGenome Browsers
NHGRI_mPanPan1-v2546,422,364 - 46,428,637 (+)NCBINHGRI_mPanPan1-v2
NHGRI_mPanPan1642,383,917 - 42,390,124 (+)NCBINHGRI_mPanPan1
Mhudiblu_PPA_v0631,606,716 - 31,612,782 (+)NCBIMhudiblu_PPA_v0Mhudiblu_PPA_v0panPan3
PanPan1.1632,492,982 - 32,499,396 (+)NCBIpanpan1.1PanPan1.1panPan2
(Canis lupus familiaris - dog)
Dog AssemblyChrPosition (strand)SourceGenome Browsers
CanFam3.1121,400,143 - 1,406,267 (+)NCBICanFam3.1CanFam3.1canFam3CanFam3.1
Dog10K_Boxer_Tasha121,535,347 - 1,541,465 (+)NCBIDog10K_Boxer_Tasha
ROS_Cfam_1.0121,542,448 - 1,548,565 (+)NCBIROS_Cfam_1.0
ROS_Cfam_1.0 Ensembl121,542,461 - 1,549,232 (+)EnsemblROS_Cfam_1.0 Ensembl
UMICH_Zoey_3.1121,399,726 - 1,405,840 (+)NCBIUMICH_Zoey_3.1
UNSW_CanFamBas_1.0121,468,093 - 1,474,210 (+)NCBIUNSW_CanFamBas_1.0
UU_Cfam_GSD_1.0121,533,422 - 1,539,539 (+)NCBIUU_Cfam_GSD_1.0
(Ictidomys tridecemlineatus - thirteen-lined ground squirrel)
Squirrel AssemblyChrPosition (strand)SourceGenome Browsers
HiC_Itri_2NW_02440494635,959,298 - 35,965,192 (+)NCBIHiC_Itri_2
SpeTri2.0 EnsemblNW_0049367271,595,499 - 1,602,215 (-)EnsemblSpeTri2.0SpeTri2.0 Ensembl
SpeTri2.0NW_0049367271,595,872 - 1,602,274 (-)NCBISpeTri2.0SpeTri2.0SpeTri2.0
(Sus scrofa - pig)
Pig AssemblyChrPosition (strand)SourceGenome Browsers
Sscrofa11.1 Ensembl724,033,740 - 24,041,179 (+)EnsemblSscrofa11.1susScr11Sscrofa11.1
Sscrofa11.1724,034,077 - 24,040,523 (+)NCBISscrofa11.1Sscrofa11.1susScr11Sscrofa11.1
Sscrofa10.2727,771,678 - 27,777,773 (-)NCBISscrofa10.2Sscrofa10.2susScr3
(Chlorocebus sabaeus - green monkey)
Green Monkey AssemblyChrPosition (strand)SourceGenome Browsers
ChlSab1.1 Ensembl1740,069,909 - 40,094,207 (-)EnsemblChlSab1.1ChlSab1.1 EnsemblchlSab2
Vero_WHO_p1.0NW_02366604431,862,788 - 31,868,803 (+)NCBIVero_WHO_p1.0Vero_WHO_p1.0
(Heterocephalus glaber - naked mole-rat)
Naked Mole-Rat AssemblyChrPosition (strand)SourceGenome Browsers
HetGla_female_1.0 EnsemblNW_00462475424,310,247 - 24,317,366 (-)EnsemblHetGla_female_1.0HetGla_female_1.0 EnsemblhetGla2
HetGla 1.0NW_00462475424,310,344 - 24,316,482 (-)NCBIHetGla_female_1.0HetGla 1.0hetGla2


Variants in Cfb
23 total Variants

QTLs in Region (mRatBN7.2)
The following QTLs overlap with this region.    Full Report CSV TAB Printer Gviewer
RGD IDSymbolNameLODP ValueTraitSub TraitChrStartStopSpecies
61472Aia1Adjuvant induced arthritis QTL 1180.001joint integrity trait (VT:0010548)joint inflammation composite score (CMO:0000919)2026463954597031Rat
2306850Pia40Pristane induced arthritis QTL 400.0001joint integrity trait (VT:0010548)joint inflammation composite score (CMO:0000919)2015279595304575Rat
1641915Colcr9Colorectal carcinoma resistance QTL 92.970.0024intestine integrity trait (VT:0010554)benign colorectal tumor number (CMO:0001795)20153065546530655Rat
2317057Aia27Adjuvant induced arthritis QTL 272.83joint integrity trait (VT:0010548)right rear ankle joint diameter (CMO:0002150)20289259726381954Rat
7411668Foco32Food consumption QTL 3280.001eating behavior trait (VT:0001431)feed conversion ratio (CMO:0001312)20136600972Rat
2305926Iddm37Insulin dependent diabetes mellitus QTL 376blood glucose amount (VT:0000188)plasma glucose level (CMO:0000042)20152784246527842Rat
1354642Despr15Despair related QTL 150.0027locomotor behavior trait (VT:0001392)amount of experiment time spent in a discrete space in an experimental apparatus (CMO:0000958)20124159021Rat
1600382Edcs3Endometrial carcinoma susceptibility QTL33.50.003uterus morphology trait (VT:0001120)percentage of study population developing endometrioid carcinoma during a period of time (CMO:0001759)20125159026Rat
61448Ciaa1CIA Autoantibody QTL 1300.001blood autoantibody amount (VT:0003725)calculated serum anti-rat type 2 collagen autoantibody titer (CMO:0001281)2026463954597031Rat
1331772Cdexp2CD45RC expression in CD8 T cells QTL 25.7CD8-positive T cell quantity (VT:0008077)blood CD45RC(high) CD8 T cell count to CD45RC(low) CD8 T cell count ratio (CMO:0001990)20362164910078919Rat
8694189Bw153Body weight QTL 1533.130.001body mass (VT:0001259)body weight gain (CMO:0000420)20129191651Rat
1300152Bp195Blood pressure QTL 1953.46arterial blood pressure trait (VT:2000000)systolic blood pressure (CMO:0000004)2036216499243559Rat
9590109Sffal8Serum free fatty acids level QTL 85.320.01blood free fatty acid amount (VT:0001553)plasma free fatty acids level (CMO:0000546)20129191651Rat
9590275Scort15Serum corticosterone level QTL 153.480.001blood corticosterone amount (VT:0005345)plasma corticosterone level (CMO:0001173)20129191651Rat
9589155Insul32Insulin level QTL 326.380.001blood insulin amount (VT:0001560)plasma insulin level (CMO:0000342)20129191651Rat
7411650Foco23Food consumption QTL 2320.70.001eating behavior trait (VT:0001431)feed conversion ratio (CMO:0001312)20129191651Rat
2317851Alcrsp22Alcohol response QTL 223.20.05response to alcohol trait (VT:0010489)duration of loss of righting reflex (CMO:0002289)20127339237Rat
1598816Memor12Memory QTL 122.4exploratory behavior trait (VT:0010471)average horizontal distance between subject and target during voluntary locomotion in an experimental apparatus (CMO:0002674)20260683647606836Rat
61432Cia1Collagen induced arthritis QTL 1joint integrity trait (VT:0010548)joint inflammation composite score (CMO:0000919)20362165614101050Rat
1641893Alcrsp7Alcohol response QTL 7response to alcohol trait (VT:0010489)duration of loss of righting reflex (CMO:0002289)20127339237Rat
6893685Bw111Body weight QTL 1112.70.004body mass (VT:0001259)body weight (CMO:0000012)20132578807Rat
9590252Scort12Serum corticosterone level QTL 1220.460.001blood corticosterone amount (VT:0005345)plasma corticosterone level (CMO:0001173)20136600972Rat
737973Pia21Pristane induced arthritis QTL 214.8joint integrity trait (VT:0010548)joint inflammation composite score (CMO:0000919)2036216564606812Rat

Markers in Region
Rat AssemblyChrPosition (strand)SourceJBrowse
mRatBN7.2203,976,300 - 3,976,398 (-)MAPPERmRatBN7.2
Rnor_6.0204,536,318 - 4,536,415NCBIRnor6.0
Rnor_5.0206,616,117 - 6,616,214UniSTSRnor5.0
RGSC_v3.4204,077,593 - 4,077,690UniSTSRGSC3.4
Celera204,054,296 - 4,054,393UniSTS
Cytogenetic Map20p12UniSTS
Rat AssemblyChrPosition (strand)SourceJBrowse
mRatBN7.2203,975,806 - 3,976,336 (-)MAPPERmRatBN7.2
Rnor_6.0204,536,380 - 4,536,909NCBIRnor6.0
Rnor_5.0206,616,179 - 6,616,708UniSTSRnor5.0
RGSC_v3.4204,077,099 - 4,077,628UniSTSRGSC3.4
Celera204,054,358 - 4,054,887UniSTS
RH 3.4 Map2053.8UniSTS
Cytogenetic Map20p12UniSTS

Genetic Models
This gene Cfb is modified in the following models/strains:


RNA-SEQ Expression
High: > 1000 TPM value   Medium: Between 11 and 1000 TPM
Low: Between 0.5 and 10 TPM   Below Cutoff: < 0.5 TPM

alimentary part of gastrointestinal system circulatory system endocrine system exocrine system hemolymphoid system hepatobiliary system integumental system musculoskeletal system nervous system renal system reproductive system respiratory system appendage
Medium 11 11 11 4 11
Low 2 11 23 7 19 7 8 11 11 11 4 8
Below cutoff 1 29 29 29 1 6 1


RefSeq Acc Id: ENSRNOT00000000477   ⟹   ENSRNOP00000000477
Rat AssemblyChrPosition (strand)Source
mRatBN7.2 Ensembl203,970,643 - 3,976,505 (+)Ensembl
Rnor_6.0 Ensembl204,536,212 - 4,542,073 (-)Ensembl
RefSeq Acc Id: ENSRNOT00000060607   ⟹   ENSRNOP00000057340
Rat AssemblyChrPosition (strand)Source
mRatBN7.2 Ensembl203,951,474 - 3,970,375 (+)Ensembl
RefSeq Acc Id: ENSRNOT00000065044   ⟹   ENSRNOP00000059051
Rat AssemblyChrPosition (strand)Source
mRatBN7.2 Ensembl203,951,474 - 3,970,375 (+)Ensembl
Rnor_6.0 Ensembl204,536,263 - 4,561,062 (-)Ensembl
RefSeq Acc Id: ENSRNOT00000075928   ⟹   ENSRNOP00000068499
Rat AssemblyChrPosition (strand)Source
mRatBN7.2 Ensembl203,951,564 - 3,970,375 (+)Ensembl
Rnor_6.0 Ensembl204,536,263 - 4,552,288 (-)Ensembl
RefSeq Acc Id: ENSRNOT00000086140   ⟹   ENSRNOP00000069622
Rat AssemblyChrPosition (strand)Source
Rnor_6.0 Ensembl204,536,203 - 4,542,947 (-)Ensembl
RefSeq Acc Id: ENSRNOT00000092698   ⟹   ENSRNOP00000075765
Rat AssemblyChrPosition (strand)Source
mRatBN7.2 Ensembl203,951,474 - 3,970,375 (+)Ensembl
Rnor_6.0 Ensembl204,536,266 - 4,561,066 (-)Ensembl
RefSeq Acc Id: NM_212466   ⟹   NP_997631
RefSeq Status: VALIDATED
Rat AssemblyChrPosition (strand)Source
GRCr8203,975,271 - 3,981,138 (+)NCBI
mRatBN7.2203,970,643 - 3,976,510 (+)NCBI
Rnor_6.0204,536,206 - 4,542,073 (-)NCBI
Rnor_5.0206,616,005 - 6,621,872 (-)NCBI
RGSC_v3.4204,072,124 - 4,077,802 (+)RGD
Celera204,054,184 - 4,060,051 (-)RGD
RefSeq Acc Id: NP_997631   ⟸   NM_212466
- Peptide Label: precursor
- UniProtKB: Q6MG74 (UniProtKB/TrEMBL),   A6KTM2 (UniProtKB/TrEMBL),   G3V615 (UniProtKB/TrEMBL)
- Sequence:
RefSeq Acc Id: ENSRNOP00000075765   ⟸   ENSRNOT00000092698
RefSeq Acc Id: ENSRNOP00000059051   ⟸   ENSRNOT00000065044
RefSeq Acc Id: ENSRNOP00000068499   ⟸   ENSRNOT00000075928
RefSeq Acc Id: ENSRNOP00000000477   ⟸   ENSRNOT00000000477
RefSeq Acc Id: ENSRNOP00000069622   ⟸   ENSRNOT00000086140
RefSeq Acc Id: ENSRNOP00000057340   ⟸   ENSRNOT00000060607
Protein Domains
Peptidase S1   Sushi   VWFA


eQTL   View at Phenogen
WGCNA   View at Phenogen
Tissue/Strain Expression   View at Phenogen

RGD ID:13701356
Promoter ID:EPDNEW_R11879
Type:initiation region
Description:complement factor B
SO ACC ID:SO:0000170
Source:EPDNEW (Eukaryotic Promoter Database,
Alternative Promoters:null; see alsoEPDNEW_R11881  
Experiment Methods:Single-end sequencing.
Rat AssemblyChrPosition (strand)Source
Rnor_6.0204,541,955 - 4,542,015EPDNEW

Additional Information

Database Acc Id Source(s)
AGR Gene RGD:2204 AgrOrtholog
BioCyc Gene G2FUF-4602 BioCyc
Ensembl Genes ENSRNOG00000000419 Ensembl
  ENSRNOG00000051158 Ensembl
  ENSRNOG00000051235 Ensembl, ENTREZGENE, UniProtKB/TrEMBL
Ensembl Transcript ENSRNOT00000000477 ENTREZGENE
  ENSRNOT00000000477.7 UniProtKB/TrEMBL
  ENSRNOT00000060607.5 UniProtKB/TrEMBL
  ENSRNOT00000065044.5 UniProtKB/TrEMBL
  ENSRNOT00000075928.3 UniProtKB/TrEMBL
  ENSRNOT00000092698.2 UniProtKB/TrEMBL
  Complement Module, domain 1 UniProtKB/TrEMBL
InterPro Compl_C2_B UniProtKB/TrEMBL
  Complement_B UniProtKB/TrEMBL
  Pept_cys/ser_Trypsin-like UniProtKB/TrEMBL
  Peptidase_S1/S6_AS UniProtKB/TrEMBL
  Peptidase_S1_PA_chymotrypsin UniProtKB/TrEMBL
  Peptidase_S1_S6 UniProtKB/TrEMBL
  Peptidase_S1A UniProtKB/TrEMBL
  Sushi/SCR/CCP_sf UniProtKB/TrEMBL
  Sushi_SCR_CCP UniProtKB/TrEMBL
  vWFA_dom_sf UniProtKB/TrEMBL
KEGG Report rno:294257 UniProtKB/TrEMBL
  PTHR46393:SF1 UniProtKB/TrEMBL
  PTHR46393:SF2 UniProtKB/TrEMBL
Pfam Sushi UniProtKB/TrEMBL
  Trypsin UniProtKB/TrEMBL
PhenoGen Cfb PhenoGen
  Complement_B UniProtKB/TrEMBL
RatGTEx ENSRNOG00000000419 RatGTEx
  ENSRNOG00000051158 RatGTEx
  ENSRNOG00000051235 RatGTEx
  Tryp_SPc UniProtKB/TrEMBL
Superfamily-SCOP Complement_control_module UniProtKB/TrEMBL
  Pept_Ser_Cys UniProtKB/TrEMBL
  SSF53300 UniProtKB/TrEMBL
UniProt A0A096MKF9_RAT UniProtKB/TrEMBL

Nomenclature History
Date Current Symbol Current Name Previous Symbol Previous Name Description Reference Status
2006-03-30 Cfb  complement factor B  Bf  B-factor, properdin  Symbol and Name updated 1299863 APPROVED
2001-07-23 Bf  Properdin factor B      Name withdrawn 67952 WITHDRAWN
2001-07-23 Bf  B-factor, properdin      Name updated to reflect Human and Mouse nomenclature 67952 APPROVED